A practical reference on AOD9604: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-07-10. Anything still debated is marked as such rather than presented as settled.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from C-terminal region of human growth hormone |
| Approximate molecular mass | About 1.8 kDa | Varies with sequence length and counterions |
| Confirmed receptor target | None established | No confirmed growth hormone receptor agonism |
| Reported in vitro activity | Lipolysis stimulation and lipogenesis inhibition | Observed mainly in adipocyte models; human relevance uncertain |
| Regulatory status | Not approved as a drug in major markets | May be treated differently across jurisdictions; not a recognized dietary ingredient in some countries |
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
== Manufacturing == Commercial preparations of lente insulin are standardized to 30% semilente (amorphous precipitates of insulin), and 70% ultralente (crystallized insulin). In early versions, the semilente insulin was extracted from pigs, and the ultralente insulin was extracted from cows.
There is evidence to suggest that excitatory amino acids like quisqualic acid play a significant role in the induction of cell death following stroke, hypoxia-ischemia, and traumatic brain injury . Studies involving the binding of quisqualic acid have indicated that the amino acid does not show selectivity for a singular specific receptor subtype, which was initially identified as the quisqualate receptor. Instead, it demonstrates high affinity for other types of excitatory amino acid receptors, including kainate, AMPA, and metabotropic receptors, as well as some transport sites, such as the chloride-dependent L-AP4-sensitive sites. In addition, it also exhibits affinity for certain enzymes responsible for cleaving dipeptides, including the enzyme responsible for cleaving N-acetyl-aspartylglutamate (NAALADase) . Regarding bioavailability, no database information is present, as there is limited research on its pharmacokinetics. However, even though the bioavailability is not well established, studies in rats suggest that age may play a role in the presence of administered quisqualic acid effects. An experiment which was done on rats within two age groups (20-days-old and 60-days-old) showed that, when given quisqualic acid microinjections, 60-day-old rats had more seizures compared to the younger rats. Additionally, the rats were given the same amount of quisqualic acid, however the immature animals received a higher dosage per body weight, implying that the harm inflicted by the excitatory amino acid may have been comparatively lower in the younger animals.
In Australia, ketamine is listed as a Schedule 8 controlled drug under the Poisons Standard (October 2015). In Canada, ketamine has been classified as a Schedule I narcotic since 2005. In December 2013, the government of India, in response to rising recreational use and the use of ketamine as a date rape drug, added it to Schedule X of the Drug and Cosmetics Act, requiring a special license for sale and maintenance of records of all sales for two years. In the United Kingdom, it was labeled a Class B drug on 12 February 2014. In 2025, the Home Office requested a review of the classification with a view to changing it to Class A, based on an increase in recreational use and the negative health consequences. The increase in recreational use prompted ketamine to be placed in Schedule III of the United States Controlled Substances Act in August 1999.
Sources: en.wikipedia.org
=== Comparison to other major staple foods === The following table shows the nutrient content of green soybean and other major staple foods, each in respective raw form on a dry weight basis to account for their different water contents. Raw soybeans, however, are not edible and cannot be digested. These must be sprouted, or prepared and cooked for human consumption. In sprouted and cooked form, the relative nutritional and anti-nutritional contents of each of these grains is remarkably different from that of raw form of these grains reported in this table. The nutritional value of soybean and each cooked staple depends on the processing and the method of cooking: boiling, frying, roasting, baking, etc.
bumping A phenomenon in which a homogeneous liquid raised to its boiling point becomes superheated and, upon nucleation, rapidly boils to the gas phase, resulting in a violent expulsion of the liquid from the container; in extreme cases, the container itself may shatter. Frequent stirring, the use of an appropriate container, and the use of boiling chips can help prevent bumping.
The cyclol hypothesis is the now discredited first structural model of a folded, globular protein, formulated in the 1930s. It was based on the cyclol reaction of peptide bonds proposed by physicist Charles Frank in 1936, in which two peptide groups are chemically crosslinked. These crosslinks are covalent analogs of the non-covalent hydrogen bonds between peptide groups and have been observed in rare cases, such as the ergopeptides. Based on this reaction, mathematician Dorothy Wrinch hypothesized in a series of five papers in the late 1930s a structural model of globular proteins. She postulated that, under some conditions, amino acids will spontaneously make the maximum possible number of cyclol crosslinks, resulting in cyclol molecules and cyclol fabrics. She further proposed that globular proteins have a tertiary structure corresponding to Platonic solids and semiregular polyhedra formed of cyclol fabrics with no free edges. In contrast to the cyclol reaction itself, these hypothetical molecules, fabrics and polyhedra have not been observed experimentally. The model has several consequences that render it energetically implausible, such as steric clashes between the protein sidechains. In response to such criticisms J. D. Bernal proposed that hydrophobic interactions are chiefly responsible for protein folding, which was indeed borne out.
== Approval and use == Tofisopam is not approved for sale in the United States or Canada. However, Vela Pharmaceuticals of New Jersey is developing the D-enantiomer (dextofisopam) as a treatment for irritable bowel syndrome, with moderate efficacy demonstrated in clinical trials so far.
Sources: en.wikipedia.org
=== Condensate microenvironment === The condensate microenvironment refers to the distinct internal physical and chemical conditions within biomolecular condensates that influence molecular behavior and biochemical activity. These environments can differ markedly from the surrounding cellular milieu in terms of material property, pH, and chemical property. Rather than acting solely as passive concentration hubs, condensates modulate their internal milieu to promote selective partitioning, regulate reaction kinetics, and enable context-specific biological functions. Experimental studies have revealed several mechanisms by which condensate microenvironments operate. The material properties of condensates have been linked to condensate composition and functions. Nucleolar condensates have been shown to maintain internal pH gradients that influence RNA processing and protein composition. Other studies have demonstrated that different nuclear condensates exhibit distinct solvent characteristics, shaping the partitioning behavior of small molecules and biochemical cofactors. Further direct evidence comes from experiments using synthetic tools to manipulate condensate material properties. One study introduced a genetically encoded peptide, killswitch, that selectively arrests condensate dynamics without disrupting their scaffolds, enabling controlled perturbation of condensate material property in live cells. This intervention altered the protein composition of transcriptional condensates and impaired their biological activity.
Cann, of the University of California, Berkeley, was the first to look at the genetics of mitochondria, passed along the female line; this led to the Mitochondrial Eve theory, who was thought to have lived 200,000 years ago; the new PCR technique allowed strands of hair to be genetically sequenced; Anna Di Rienzo developed the mitochondrial genetics technique at Berkeley, and dated Homo Sapiens to have left Africa around 100,000 years ago; the Cro-Magnon appeared in Eastern Europe 40,000 years ago, who were the first to eat fish; Paul Mellars of University of Cambridge; the Vézère valley in France, with a Cro-Magnon cave, from the upper palaeolithic era; Lawrence H. Keeley at the University of Illinois Chicago; Philip Lieberman and the shape of the human tongue, and impacted molars. Narrated by Gillian Hanna, produced by Ray Fitzwalter, directed by David Hart (both former World in Action executives, which was produced by Granada Television), made by Granada Television. 17 November Teaching Computers to Think, about early machine learning, with John G.
== Browsing, searching and data mining PRIDE == Currently, data can be queried from PRIDE via the PRIDE web interface, through the stand-alone Java client PRIDE Inspector, or coupled directly to several search engines through PeptideShaker. Moreover, a new RESTful API allows convenient programmatic access to the PRIDE archive. The extensive use of controlled vocabularies (CVs) and ontologies for flexible yet context-sensitive annotation of data, along with the ability to perform intelligent queries by these annotations, are key features of PRIDE.
Sources: en.wikipedia.org
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.
It is not approved as a prescription drug in the United States or the European Union for any indication. Regulatory status can differ by country, and it is often sold as a research chemical or in unapproved products. Such products are not equivalent to an approved medicine.
In the studies reported so far, AOD9604 does not appear to act through the growth hormone receptor and has not shown the typical IGF-1 increase caused by full-length hGH. Human data are limited, so this remains an area of uncertainty. It should not be assumed to have the same effects as hGH.
Lyophilized powder is commonly stored at −20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept refrigerated and used within a limited period.